ALDX - Aldeyra Therapeutics to Participate in the Jefferies Global Healthcare Conference
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a clinical-stage biotechnology company developing innovative therapies for the treatment of immune-mediated and metabolic diseases, today announced that Todd C. Brady, M.D., Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference.
Dr. Brady’s conversation with Kelly Shi, Ph.D., Senior Vice President, Biotechnology Equity Research at Jefferies, is scheduled to begin at 3:30 p.m. ET Wednesday, June 5, 2024. To view the live webcast, log in to the Investors & Media section of the Aldeyra website at https://ir.aldeyra.com . Following the fireside chat, the webcast will be archived for 90 days.
About Aldeyra
Aldeyra Therapeutics is a biotechnology company devoted to discovering innovative therapies designed to treat immune-mediated and metabolic diseases. Our approach is to develop pharmaceuticals that modulate protein systems, instead of directly inhibiting or activating single protein targets, with the goal of optimizing multiple pathways at once while minimizing toxicity. Our product candidates include RASP (reactive aldehyde species) modulators ADX-629, ADX-246, ADX-248, and chemically related molecules for the potential treatment of immune-mediated and metabolic diseases. Our late-stage product candidates are reproxalap, a RASP modulator for the potential treatment of dry eye disease and allergic conjunctivitis, and ADX-2191, a novel formulation of intravitreal methotrexate for the potential treatment of retinitis pigmentosa.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240529826900/en/
Investor & Media Contact:
David Burke
Tel: (917) 618-2651
investorrelations@aldeyra.com